talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.